Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
APRE Aprea Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: APRE
Price (delayed)
$1.81
Market cap
$10.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.35
Enterprise value
-$9.3M
Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor
Highlights
APRE's EPS is up by 29% year-on-year
Aprea Therapeutics's revenue has increased by 33% YoY but it has decreased by 15% from the previous quarter
The company's gross profit rose by 33% YoY but it fell by 15% QoQ
The quick ratio has contracted by 47% YoY and by 16% from the previous quarter
The equity has contracted by 46% YoY and by 19% from the previous quarter
Key stats
What are the main financial stats of APRE
Market
Valuations
Earnings
Shares outstanding
5.53M
Market cap
$10.01M
Enterprise value
-$9.3M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
8.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-7.24
Revenue
$1.28M
Gross profit
$1.28M
Operating income
-$15.26M
Net income
-$14.08M
EBIT
-$15.29M
EBITDA
-$15.27M
Free cash flow
-$13.26M
Per share
Balance sheet
Liquidity
EPS
-$2.35
EPS diluted
-$2.35
Free cash flow per share
-$2.21
Book value per share
$2.83
Revenue per share
$0.21
TBVPS
$3.37
Total assets
$20.22M
Total liabilities
$4.67M
Debt
$0
Equity
$15.55M
Working capital
$16.47M
Debt to equity
0
Current ratio
5.9
Quick ratio
5.75
Net debt/EBITDA
1.26
Margins
Efficiency
Dividend
EBITDA margin
-1,188.8%
Gross margin
100%
Net margin
-1,096.3%
Operating margin
-1,187.7%
Return on assets
-55.7%
Return on equity
-68.4%
Return on invested capital
N/A
Return on capital employed
-90.7%
Return on sales
-1,190.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APRE stock price
How has the Aprea Therapeutics stock price performed over time
Intraday
-6.7%
1 week
0.28%
1 month
3.43%
1 year
-60.57%
YTD
-44.98%
QTD
-11.27%
Financial performance
How have Aprea Therapeutics's revenue and profit performed over time
Revenue
$1.28M
Gross profit
$1.28M
Operating income
-$15.26M
Net income
-$14.08M
Gross margin
100%
Net margin
-1,096.3%
Aprea Therapeutics's revenue has increased by 33% YoY but it has decreased by 15% from the previous quarter
The company's gross profit rose by 33% YoY but it fell by 15% QoQ
The net margin has declined by 27% since the previous quarter but it has grown by 17% year-on-year
The company's operating margin fell by 25% QoQ but it rose by 18% YoY
Price vs fundamentals
How does APRE's price correlate with its fundamentals
Growth
What is Aprea Therapeutics's growth rate over time
Valuation
What is Aprea Therapeutics stock price valuation
P/E
N/A
P/B
0.64
P/S
8.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-7.24
APRE's EPS is up by 29% year-on-year
APRE's P/B is 62% below its 5-year quarterly average of 1.7 and 20% below its last 4 quarters average of 0.8
The equity has contracted by 46% YoY and by 19% from the previous quarter
APRE's P/S is 36% below its last 4 quarters average of 13.2
Aprea Therapeutics's revenue has increased by 33% YoY but it has decreased by 15% from the previous quarter
Efficiency
How efficient is Aprea Therapeutics business performance
APRE's return on sales is down by 26% since the previous quarter but it is up by 18% year-on-year
The company's return on equity fell by 26% QoQ and by 20% YoY
Aprea Therapeutics's ROA has decreased by 22% from the previous quarter and by 21% YoY
Dividends
What is APRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APRE.
Financial health
How did Aprea Therapeutics financials performed over time
The quick ratio has contracted by 47% YoY and by 16% from the previous quarter
The current ratio has decreased by 47% YoY and by 16% from the previous quarter
The debt is 100% smaller than the equity
The equity has contracted by 46% YoY and by 19% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.